Transduction with chimeric T-cell receptor genes can be used to redirect primary T lymphocytes to recognize specific antigens (Ags), including ovarian and breast cancer Ags. To extend this approach to colon cancer we report here redirection of T cells using a chimeric receptor recognizing the colon cancer-associated Ag EGP40. Chimeric T cell receptors were constructed by ligating single-chain genes of either of two EGP40-specific monoclonal antibodies (CO17.1A, GA733) to the Fc receptor ␥-signaling chain. Retroviral vectors incorporating these constructs were used to transduce a murine T-cell line and human peripheral blood lymphocytes. These modified T cells were analyzed for specific recognition of colon cancer lines by measuring cytokine release and lytic activity against tumor targets. Murine lymphocytes transduced with the chimeric receptor based on GA733, but not CO17.1A, released cytokine specifically in response to EGP40-expressing colon cancer cell lines. Recognition of colon cancer targets by murine lymphocytes was blocked by the addition of GA733 antibody or soluble EGP40 Ag, confirming that colon cancer recognition is based on specific chimeric receptor-Ag interaction. Human lymphocytes transduced with chimeric GA733 specifically recognized colon carcinoma cells in cytokine release assays and lysed EGP40-expressing tumor cells. Genetic modification of T cells can be used to redirect T cells against EGP40-expressing tumor cells. The expression of chimeric GA733 in the autologous lymphocytes of patients may provide a source of tumor-reactive cells with therapeutic application against colon cancer. Cancer Gene Therapy (2000) 7, 284 -291
O ver 130,000 new cases of colorectal cancer are diagnosed annually in the United States, with close to 25,000 of these individuals bearing distant metastasis. More than 54,000 deaths occur each year due to colorectal cancer. (Seer Cancer Review, National Cancer Institute, Bethesda, Md).
Once metastases have spread beyond locoregional lymph nodes, few effective options are available for the treatment of colon cancer. Individuals with metastases isolated to the liver have been treated with surgical resection, resulting in a 36% 5-year survival in uncontrolled studies. 1 Standard systemic treatment with 5-fluorouracil-based combination chemotherapy for nonresectable metastatic disease mediates a 3-48% objective response without a significant improvement in survival. 2, 3 In addition, a randomized trial revealed some reduction in recurrence of disease in postoperative colon cancer patients after vaccination with autologous tumor and bacillus Calmette-Guérin. 4 In light of the limited effectiveness of these treatments, many would benefit from new treatment modalities for metastatic colon cancer.
Immunotherapy consisting of interleukin-2 (IL-2) administration or the adoptive transfer of tumor-infiltrating lymphocytes can be an effective form of treatment against some cancers, 5-7 but not against colon cancer. Patients with colon cancer have responded infrequently to IL-2 therapy, 8 -10 and tumor-infiltrating lymphocytes recognizing colon cancer have been difficult to isolate. 11 It may be possible to extend immunotherapy to colon cancer if cytotoxic T cells can be redirected to recognize colon cancer antigen (Ag) as a target.
We have demonstrated previously that T cells may be redirected by transduction with a gene construct encoding a chimeric T cell receptor (cTCR) composed of an extracellular Ag recognition domain linked to a transmembrane and intracellular signaling domain. T cells transduced with cTCRs specific for tumor-associated Ag 12 were redirected to lyse ovarian tumor cells in vitro. In further investigations, we demonstrated the antitumoral potential of redirected T cells in mice bearing tumors expressing a human ovarian cancer Ag. 13 The signaling chain components were composed of either the -chain of the CD3-TCR complex or of the ␥ subunit normally associated with Fc receptors (FcRs). With this protein expressed on the cell surface, the extracellular Ag recognition portion bound directly to Ag expressed on the surface of target cells. After this engagement, the signal for lymphocyte activation was propagated intracellularly through the immunoreceptor tyrosine-based activation motifs on the signaling chain.
14 Surface proteins of a closely related gene family 15, 16 are overexpressed on colon cancer cells, the prototypic protein of which has been variably identified as EGP40, 17 17-1A, 18 or GA733-2, 19 and appears to function as a cell-cell or cell-matrix adhesion molecule. 20 The molecule is ubiquitously overexpressed on colon cancer and at lower levels on the normal colon, pancreas, and lung. 18 The Ag is recognized by the antibodies (Abs) CO17.1A and GA733, 21, 22 each recognizing separate but possibly overlapping epitopes. 23 The expression pattern of EGP40 makes it a potential target Ag for Ab-directed immunotherapy. Preclinical studies demonstrating tumor inhibition in mice after administration of CO17.1A 24 have led to phase II trials of this Ab in colorectal carcinoma patients. A significant increase in the survival of monoclonal Ab-treated patients has been reported. 25 Anti-idiotype Abs that mimic the EGP40 Ag have also shown promise when used as an immunogen. 26 In addition, the antitumoral potential of bispecific Abs incorporating specificity for CO17.1A is being investigated. 27 As an alternative approach to immunotherapy of colon cancer, we designed cTCRs to recognize colon cancers expressing the surface protein EGP40. We constructed genes encoding the variable portion of the immunoglobulins (Igs) CO17.1A and GA733 linked to the FcR-␥ signaling subunit. 28 We assessed the ability of the cTCRs expressed in murine and human lymphocytes to redirect the lymphocytes to specifically recognize colon cancer cell lines.
MATERIALS AND METHODS

Cells and culture media
The retroviral packaging cell lines PA317 (American Type Culture Collection, Manassas, Va) and GP ϩ E86 (kindly provided by Dr. A Bank, Columbia University, New York, NY) were cultured in transduction media composed of Dulbecco's modified Eagle's medium supplemented with additives: 10% fetal calf serum, 2 mM glutamine, nonessential amino acids, 1 mM sodium pyruvate, and antibiotics consisting of 100 U/mL penicillin, 100 g/mL streptomycin (all from Biofluids, Rockville, Md), 50 g/mL gentamicin sulfate (BioWhittaker, Walkersville, Md), and 1.25 g/mL amphotericin (Fungizone, Life Technologies, Grand Island, NY). The murine T-cell line 14.1 (kindly provided by Dr. J. Berzofsky, National Institutes of Health, Bethesda, Md) is a clonal CD4 ϩ line specific for an epitope of sperm whale myoglobin. 29 These cells were cultured in 14.1 media composed of a 1:1 mixture of Eagle-Hanks' amino acid and RPMI 1640 with additives and 300 international units/mL IL-2 (Chiron, Emeryville, Calif). Cell density was maintained at ϳ5 ϫ 10 5 /mL by splitting cultures 1:5 every 4 days. Peripheral blood mononuclear cells (PBMCs) from normal healthy adult volunteers were cultured in media, designated peripheral blood lymphocyte (PBL) media, consisting of RPMI 1640 (Biofluids) with 10% human A/B sera (male, heat-inactivated, Sigma, St. Louis, Mo), 600 U/mL IL-2, and antibiotics. Hybridoma cells, a human ovarian cancer cell line (IGROV-1), a human erythroleukemia line (K562), a human lymphoma line (DAUDI), human melanoma lines (1143mel, 888mel, and 624.38mel), and human colon cancer lines (HCT 116, SW620, and CY13) were cultured in RPMI 1640 with additives.
Chimeric TCR gene construction
Genomic DNA was isolated from the hybridomas that produce the Abs BR3E4 30 and FG1 31 (anti-CO17.1A and anti-GA733 idiotypes, respectively). Gene fragments encoding the Ig V region heavy (V H ) or V region light (V L ) chains were amplified by polymerase chain reaction (PCR) using oligodeoxynucleotide primers designed to complement the 5Ј and 3Ј consensus sequences for these regions. These V L and V H fragments were joined by a 14-aa linker to form a single chain Fv. 32 To accomplish this, the V L 3Ј and V H 5Ј primers included additional terminal nucleotide bases that introduced the 5Ј and 3Ј sequence of the linker, respectively, with an SalI site (primers, SalI italicized: V L 3Ј, CCC GTC GAC CCT TTT ATT TCC AGC TTT GTG CC; V H 5Ј, CGG GTC GAC TTC CGG TAG CGG CAA ATC TCT GAA GGC AAA GGT CAG GTC CAG CTG GAG GAG TCT GG). In addition, PCR primers for the V L 5Ј and V H 3Ј regions were designed to introduce XbaI and BstEII restriction endonuclease sites, respectively (primers: XbaI italicized: V L 5Ј, CCC GTC TAG AGG GAA CAT TGT AAT GAC CCA ATC TCC CAA ATC CAT GTC CAT GTC; BstEII italicized: V H 3Ј, TGA AGA GAC GGT GAC CGT AGT CCC TTG GCC CCA G). PCR V L and V H products were purified and digested with XbaI/SalI or BstEII/SalI, respectively, and ligated at their common SalI site and into an XbaI/BstEII digest of the MOv-␥ pRSV vector (constructed previously for synthesis of the MOv-␥ receptor recognizing ovarian cancer), 12 resulting in an SC15 light chain leader and ␥-chain sequences flanking the 5Ј and 3Ј ends of the single chain Fv gene, respectively. Escherichia coli DH5␣ were transformed with the ligation mixture, and minipreps of transformed colonies were screened by restriction digest, amplified, and confirmed to be accurate by sequence analysis. Using this methodology, cTCRs based on the CO17.1A and GA733 Igs were constructed (CO17.1A-␥ and GA733-␥), each recognizing the EGP40 Ag overexpressed on colon cancer cells.
Generation of retroviral vectors
The finished constructs were removed from the pRSV vector using an SnaBI/XhoI digest, and the resulting fragment was ligated into an HpaI/XhoI digest of the pLXSN retroviral vector. In this vector, transcription of the CO17.1A-␥ or GA733-␥ chimeric TCR gene is controlled by a long terminal repeat (LTR) promoter from Moloney murine leukemia virus. Neomycin phosphotransferase II as a selectable marker is under the control of a simian virus 40 promoter (Fig 1) .
After purification and amplification, the plasmid was introduced into PA317 amphotropic retroviral packaging cells 33 by calcium phosphate transfection using a commercially available kit (Stratagene, La Jolla, Calif) as described previously. 12 At 48 hours posttransfection, packaging lines were selected using 600 g/mL of G418 (Geneticin; Life Technologies) for 7 days.
Packaging cells were generated to produce three distinct groups of retrovirus: LXSN is the retroviral vector not expressing a protein following the LTR promoter; LCO17.1A-␥SN and LGA733-␥SN each contain genes expressing a cTCR.
Transduction of NIH 3T3
The murine fibroblast line NIH 3T3 was transduced using retroviral supernatant. Confluent packaging cell lines for the three vectors were overlaid with transduction media and cultured for 16 -24 hours. Resultant supernatant was harvested, filtered, and supplemented with polybrene (8 g/mL, Sigma). NIH 3T3 cells (ϳ30% confluent) were overlaid with fresh supernatant daily for 3 days followed by continuous culture in transduction media supplemented with G418 (800 g/mL).
Transduction of 14.1 cell lines
Murine 14.1 lymphocytes were transduced by coculture with selected bulk packaging lines. To accomplish this, packaging lines (5 ϫ 10 6 cells) were plated in tissue culture flasks with transduction media and changed 24 hours later to a 1:1 mix of transduction media and 14.1 media. After 48 hours of packaging line culture, 14.1 lymphocytes (5 ϫ 10 6 ) were added along with IL-2 (300 U/mL) and polybrene (8 g/mL). Murine 14.1 cultures were established in the following groups: no vector (not transduced), LXSN, LCO17.1A-␥SN, and LGA733-␥SN. After 48 hours of coculture, the nonadherent 14.1 cells were harvested and cultured separately. Cells were passaged to fresh flasks on 3 successive days to eliminate any adherent packaging line. The remaining transduced 14.1 lymphocytes were then maintained continuously in selection (G418, 500 g/mL).
Transduction of human PBLs
Retroviral supernatants (transduction media) were prepared daily from confluent packaging cells in a T-175 tissue culture flask. Supernatants were filtered to remove all packaging cells and supplemented with IL-2 (600 U/mL) and polybrene (8 g/mL). PBMCs were isolated by differential density centrifugation over a Ficoll-Hypaque gradient at a specific gravity of 1.077 (Organon Teknika, Durham, NC). PBMCs were washed, counted, and plated in a 24-well plate at 1 ϫ 10 6 cells/well in retroviral supernatant with OKT3 (10 ng/mL). One-half of the media was removed every 12 hours and replaced with fresh retroviral supernatant for 72 hours. PBLs were transduced to establish the no vector, LXSN, and LGA733-␥SN groups. At 96 hours, the cells were resuspended in PBL media and selected with G418 (500 g/mL). Cells were selected for 5 days and subsequently resuspended in PBL media without G418. Cell density was adjusted (1 ϫ 10 6 cells/mL) with the addition of fresh media every 48 hours. PBLs were tested for phenotype (CD4/CD8, CD3/CD56) and cytokine release on day 14 of culture.
Flow cytometric analysis
To determine the expression of cTCRs on the surface of NIH 3T3 cells, 14.1 cells, and human PBLs, as well as the phenotype of cultured human PBLs, a flow cytometric analysis was performed using 1.5 ϫ 10 6 cells/sample in phosphate-buffered saline/0.5% bovine serum albumin/0.01% azide (fluorescenceactivated cell sorter (FACS) buffer). To analyze the surface expression of the cTCR, the rat anti-idiotype Abs BR3E4 and FG1 (CO17.1A and GA733 anti-idiotypes, respectively) were used as the primary monoclonal Ab, whereas fluorescein isothiocyanate-conjugated goat anti-rat Ig (Becton Dickinson, Lincoln Park, NJ) was used as the secondary Ab. Cells were incubated with 20 L of primary Ab (50 g/mL) for 30 minutes at 4°C, washed four times with FACS buffer, and subsequently incubated with 20 L of a 1/5 dilution of secondary Ab solution for 30 minutes at 4°C. Expression of the phenotypic markers CD3, CD56, CD4, and CD8 on human PBLs was determined by a single 30-minute incubation with fluorescein isothiocyanate-or phycoerythrin-conjugated Abs specific for these Ags (Becton Dickinson). After four more washes, analysis was completed on a FACScan flow cytometer equipped with a 488-nm laser (Becton Dickinson).
Cytokine release assays
In studies with murine lymphocytes, 1 ϫ 10 6 14.1 cells were combined with tumor cells (5 ϫ 10 5 ) in 1 mL of 14.1 media in a 24-well plate. Targets included three tumor cell lines not expressing EGP40 (DAUDI, 1143mel, and IGROV-1), three colon tumor lines (HCT 116, CY13, and SW620) all expressing the Ag, or media alone (minimum stimulation). In human studies, transduced PBLs (2 ϫ 10 5 ) were cocultured with tumor targets (888mel, IGROV-1, HCT 116, and CY13; 1 ϫ 10 5 ) in 96-well plates. In all studies, supernatants were harvested after incubation for 24 hours (37°C, 5% CO 2 ), centrifuged to remove cell debris, and stored at Ϫ70°C until determination of cytokine levels. Analysis of murine interferon-␥ (mIFN-␥) or human granulocyte-macrophage colony-stimulating factor (GM-CSF) was accomplished with commercially available enzyme-linked immunosorbent assay kits (Endogen, Cambridge, Mass, or R&D Systems, Minneapolis, Minn, respectively).
Blocking with GA733 Ab or EGP40 Ag the subsequent cell-free supernatant was stored at Ϫ70°C until being tested for mIFN-␥ concentration by commercial enzymelinked immunosorbent assay as described previously. Soluble EGP40 was generated as described previously from a baculovirus-insect cell expression system using a truncated version of the EGP40 gene (lacking the transmembrane and cytoplasmic sequences). 34 Tumor lines and 14.1 cells were cocultured in the groups and cell concentrations outlined for the Ab-blocking studies, along with the soluble EGP40 Ag or ovalbumin as a control Ag, at 0.0, 1.1, 3.3, 10.0, and 30.0 g/mL. At 24 hours, supernatant was processed for an analysis of mIFN-␥ concentration as outlined above.
Cellular cytotoxicity assays
GA733-␥ cTCR was assessed for its ability to mediate target cell lysis by incubation of transduced lymphocytes with EGP40 ϩ tumor cells. Lymphocytes transduced with LGA733-␥SN or LXSN were incubated with 5 ϫ 10 3 51 Cr-labeled EGP40 ϩ or EGP40 Ϫ tumor cells in 200 L of RPMI 1640 in 96-well plates. Supernatant was harvested after 8 hours, and specific 51 Cr release was determined as described previously.
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Due to high background levels of nonspecific lysis, unlabeled K562 cells were included in each well at a ratio of 30:1 to target cells.
RESULTS
Expression of cTCRs
Flow cytometric labeling with anti-idiotypic Abs demonstrated significant levels of surface expression of the cTCRs on packaging cells (Fig 2) . Comparable levels of cTCR were also demonstrated on the surface of 3T3 cells transduced with retroviral vectors (data not shown). However, surface expression of the cTCRs was too low to be demonstrated by flow cytometric analysis in murine and human lymphocytes, although these cells were successfully transduced with retroviral vector because they were resistant to G418. Further evidence for the surface expression of cTCRs was derived from the ability of cTCRs to endow lymphocytes with functional reactivity, as outlined below.
14.1 lymphocytes transduced with GA733-␥ but not CO17.1A-␥ respond to EGP40 ϩ targets Transduced 14.1 lymphocytes were analyzed for IFN-␥ production, after incubation with tumor cells, as an indication of their activation via their cTCR. Murine 14.1 cells transduced with the GA733-␥ cTCR released a greater level of IFN-␥ in response to the EGP40 ϩ colon cancer lines (CY13, HCT 116, and SW620) than in response to the EGP40 Ϫ controls (Fig 3) . This recognition was specific for EGP40 ϩ targets, because GA733-␥-transduced lymphocytes did not release IFN-␥ when incubated with the EGP40 Ϫ lines 24JK, DAUDI, and 1143mel. Lymphocyte activation was also dependent upon GA733-␥ expression, because lymphocytes transduced with vector lacking GA733-␥ did not secrete IFN-␥. Surprisingly, lymphocytes transduced with the cTCR CO17.1A-␥ did not respond to the EGP40 ϩ targets. Tumor cell recognition by GA733-␥ is blocked by soluble Ab or Ag Murine 14.1 lymphocytes expressing GA733-␥ were specifically activated when incubated with colon carcinoma cell lines. To confirm that this recognition was based on binding of the Ig portion of the cTCR to EGP40, we incubated 14.1 lymphocytes expressing GA733-␥ with colon cancer cells in the presence of varying concentrations of the parental Ab (GA733) or soluble EGP40 Ag. Increasing the concentration of soluble GA733 or soluble EGP40 blocked the release of mIFN-␥ from lymphocytes transduced with GA733-␥ (Fig 4) . This effect was specific for the GA733-␥-EGP40 interaction, because incubation with equivalent concentrations of control Ab or protein did not inhibit IFN-␥ release.
Human PBLs transduced with GA733-␥ recognize colon cancer cells Human PBLs from normal volunteers were divided into the following groups: nontransduced, transduced with LXSN, or transduced with GA733-␥ cTCR in the LXSN backbone. All groups proliferated at similar rates, were Ͼ90% CD3 ϩ , and maintained equivalent CD4:CD8 ratios (CD8 74.5-84.1% in the experiment shown). Lymphocytes transduced with GA733-␥ were activated when incubated with colon cancer cell lines expressing high levels of EGP40 as judged by GM-CSF release ( Fig  5) . Activation was dependent upon GA733-␥ expression, because lymphocytes that were nontransduced or transduced with vector lacking cTCR insert secreted significantly lower levels of GM-CSF in response to EGP40 ϩ tumor cells. Lymphocyte activation was also specific for EGP40 Ag, because significantly lower levels of GM-CSF were detected in supernatant from cocultures of GA733-␥-transduced lymphocytes and the EGP40 Ϫ cell lines 888mel and IGROV-1. Similar results to those presented were obtained in repeat experiments with transduced lymphocytes from several donors.
Human PBLs transduced with GA733-␥ specifically lyse EGP40
ϩ tumor cells
The capacity of GA733-␥ to redirect cytotoxic T lymphocytes (CTLs) to lyse colon cancer cell lines was assessed using a 51 Cr-release cytotoxicity assay (Fig 6) . GA733-␥-transduced PBLs lysed a significantly greater percentage of EGP40 ϩ HCT116 colon carcinoma cells than did LXSN-transduced lymphocytes, thereby demonstrating the requirement for cTCR expression for redirected lysis. In addition, redirected lysis was dependent upon EGP40 Ag expression, because GA733-␥-transduced lymphocytes lysed the EGP40 Ϫ cell line 624.38mel at background levels that were similar to those observed for nontransduced PBLs against 624.38mel cells.
DISCUSSION
Immunotherapy trials have demonstrated that CTLs can effectively treat melanoma, 7 but it has been difficult to extend this treatment to other tumor types. CTLs lyse tumor cells following the complex mechanism of specific TCR engagement with the MHC class I on the tumor cells presenting the epitopes that define a tumor regression Ag. 35 Extension of this treatment to other tumor types may require identification of tumor regression Ags for each tumor type, their MHC-restricted epitopes, and methods to specifically expand the CTLs recognizing these epitopes.
To bypass these requirements, some investigators have introduced cTCRs into lymphocytes. 36 These redirected lymphocytes are then able to be activated directly by surface-expressed Ags in an MHC-nonrestricted manner.
Initially, we demonstrated in experimental models that T cells expressing a cTCR can lyse tumor cells overexpressing the ovarian cancer-associated Ag, folate binding protein, in vitro, 12 and can treat folate binding protein-expressing tumors in mice. 13 In addition, an antitumoral response was induced in mice using bone marrow cells transduced with a cTCR. 37 Other groups have used lymphocytes bearing cTCRs against haptenated tumor cells 38 or tumor cells overexpressing Her-2/neu, 39, 40 CD44v6, 41 or G250. 42 CTLs have also been redirected using cTCRs recognizing tumor cells sensitized with tumor-specific IgE. 43 Virus-infected cells are also a potential target of cTCR-transduced lymphocytes, as demonstrated in studies with human immunodeficiency virus-infected cells expressing gp120. 44 In the current experiments, we have used this strategy to endow both murine and human lymphocytes with the ability to recognize colon cancer lines overexpressing the Ag EGP40. Genes of cTCRs based on the Abs CO17.1A and GA733 both encode an active surface molecule that binds anti-idiotypic Abs on retroviral packaging cell lines and 3T3 cells. We found that only lymphocytes transduced with the cTCR GA733-␥, and not those transduced with CO17.1A-␥, recognize tumors overexpressing the EGP40 Ag. This observation is consistent with the finding that CO17.1A Fab fragments do not bind to EGP40 Ag, whereas GA733 Fab fragments do (D.H., unpublished data). In addition, the affinity of the native GA733 monoclonal Ab is greater than that of native CO17.1A (5 ϫ 10 8 M Ϫ1 compared with 0.7 ϫ 10 8 M Ϫ1 ). 22 Alternatively, GA733-␥ may be expressed at higher levels than CO17.1A on lymphocytes. No surface expression of either cTCR could be detected on lymphocytes, although the surface expression on transduced 3T3 cells was comparable for both cTCRs.
It would be of interest to determine the exact nature of the effector cells responsible for tumor recognition in both cytokine and cytotoxicity assays with human PBLs. It is likely that the major effectors are T cells, because Ͼ90% of cells are CD3 ϩ . However, the individual contribution of CD4 ϩ and CD8 ϩ cells is not clear. It is also possible that a low number of transduced natural killer-like cells (Ͻ10%) (CD56 ϩ , CD3 Ϫ ) contribute to the observed Ag reactivity.
Several characteristics of the EGP40 Ag make it attractive as a target for treatment using a cTCR. The Ag is ubiquitously overexpressed on the surface of colon cancer cells, as well as other gastrointestinal malignancies. 18 The Ag does not have a natural soluble form that could interfere with competitive binding. 45 In contrast, an antigenic target such as carcinoembryonic Ag has a soluble form that can be found in patient sera. This is important because, as found in our blocking studies, a soluble truncated form of our target Ag blocks the activation of lymphocytes transduced with our cTCR. In addition, this Ag is recognized by several gastrointestinal carcinoma-specific Abs, including CO17.1A and GA733. 22 In the clinic, treatment with CO17.1A prolonged remission and survival in a randomized trial involving Dukes' C colorectal carcinoma patients. 25 A potential disadvantage to using this antigenic target is the expression of the Ag on normal intestinal mucosal cells. 21 Both of the Abs (CO17.1A 46 and GA733 47 ) have been administered to patients with metastatic colon cancer in phase I trials. In one such trial, GA733 was administered to five patients with gastrointestinal primaries (four colorectal patients, one pancreatic patient). At subsequent biopsy, it was determined that GA733 had bound to the primary tumor and metastatic sites. Selflimited gastrointestinal toxicity, with abdominal cramping, nausea, vomiting, and diarrhea lasting 2-4 hours after Ab infusion, was seen in patients that had been administered the highest level of Abs (three of five patients). 47 It is not clear that GA733-␥-bearing T cells adoptively transferred to patients will result in intestinal mucosal toxicity. However, if this toxicity is problematic, clinical administration of these cells by hepatic artery infusion may decrease the effector cell burden to normal mucosa, thereby decreasing mucosal injury. In addition to minimizing this toxicity, infusion via the hepatic vascular bed should promote a first pass effect through the organ most susceptible to metastasis from this disease. For these reasons, regional delivery of GA733-␥-bearing T cells via hepatic artery infusion may be the optimal route of administration in eventual clinical trials.
These initial studies demonstrate that the cTCR GA733-␥ transduced into lymphocytes redirects those lymphocytes to recognize EGP40-expressing targets. Further work is in progress to optimize the expression of these receptors in human lymphocytes and bone marrow as well as to elucidate their activity in vivo. Lymphocytes redirected by this cTCR are a promising reagent for the adoptive therapy of colon cancer.
